• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Malignant Pleural Mesothelioma - Pipeline Review, H2 2012 Product Image

Malignant Pleural Mesothelioma - Pipeline Review, H2 2012

  • Published: July 2012
  • 91 pages
  • Global Markets Direct

Malignant Pleural Mesothelioma – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Malignant Pleural Mesothelioma - Pipeline Review, H2 2012', provides an overview of the Malignant Pleural Mesothelioma therapeutic pipeline. This report provides information on the therapeutic development for Malignant Pleural Mesothelioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma. 'Malignant Pleural Mesothelioma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Malignant Pleural Mesothelioma.
- A review of READ MORE >

2
List of Tables 6
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Malignant Pleural Mesothelioma Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Malignant Pleural Mesothelioma 9
Malignant Pleural Mesothelioma Therapeutics under Development by Companies 11
Malignant Pleural Mesothelioma Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Malignant Pleural Mesothelioma Therapeutics – Products under Development by Companies 17
Malignant Pleural Mesothelioma Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Malignant Pleural Mesothelioma Therapeutics Development 19
Plexxikon Inc. 19
Pfizer Inc. 20
AEterna Zentaris Inc. 21
Morphotek, Inc. 22
CanBas Co., Ltd. 23
MolMed S.p.A. 24
Polaris Group 25
Malignant Pleural Mesothelioma – Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 33
CBP501 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
NGR-hTNF - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
NGR-hTNF + Doxorubicin - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Cisplatin + Interferon Alfa + Radiation Therapy - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
BMS-354825 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
SU11248 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Pazopanib - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
CBP501 + Cisplatin + Pemetrexed - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 47
BG00001 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
PLX 3397 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ADI-PEG 20 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
NGR-hTNF + Gemcitabine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
NGR-hTNF + Vinorelbine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
PF-03446962 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
MORAb-009 + Pemetrexed + Cisplatin - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
RAD001 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Celecoxib + Decitabine + FK228 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 62
FR901228 + Flavopiridol - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Bortezomib - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
K562-GM Vaccine + Cyclophosphamide + Celecoxib - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
SCH 721015 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Cediranib Maleate + Cisplatin + Pemetrexed - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Vinorelbine5 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Erbitux + Cisplatin - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Gemcitabine + Cisplatin - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Cisplatin + Pemetrexed - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Cisplatin + Pemetrexed + Vorinostat - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Autologous Mesothelin Re-Directed T Cells - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Malignant Pleural Mesothelioma Therapeutics – Drug Profile Updates 76
Malignant Pleural Mesothelioma Therapeutics - Dormant Products 85
Malignant Pleural Mesothelioma – Product Development Milestones 86
Featured News & Press Releases 86
Jun 04, 2012: MolMed Presents Long-Term Follow Up Data From Phase II Mesothelioma Trial Of NGR-hTNF At ASCO 86
Jun 01, 2012: Bionomics To Present Clinical Trial Data Of BNC105 At ASCO Meeting 86
May 31, 2012: Aeterna Zentaris Announces Pubication Of New Data On Perifosine In Plos One 87
Nov 01, 2011: Canbas Enrolls Last Patient In Phase II Trial Of CBP501 As First-Line Treatment Of Malignant Pleural Mesothelioma 87
Sep 23, 2011: Merck's ZOLINZA Fails Primary Endpoint In Phase III Mesothelioma Study 88
Dec 10, 2008: CBP501 Enters Phase II Trials For The Treatment Of Malignant Pleural Mesothelioma 88
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 91
Disclaimer 91

List of Tables
Number of Products Under Development for Malignant Pleural Mesothelioma, H2 2012 9
Products under Development for Malignant Pleural Mesothelioma – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Plexxikon Inc., H2 2012 19
Pfizer Inc., H2 2012 20
AEterna Zentaris Inc., H2 2012 21
Morphotek, Inc., H2 2012 22
CanBas Co., Ltd., H2 2012 23
MolMed S.p.A., H2 2012 24
Polaris Group, H2 2012 25
Assessment by Monotherapy Products, H2 2012 26
Assessment by Combination Products, H2 2012 27
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Stage and Molecule Type, H2 2012 32
Malignant Pleural Mesothelioma Therapeutics – Drug Profile Updates 76
Malignant Pleural Mesothelioma Therapeutics – Dormant Products 85

List of Figures
Number of Products under Development for Malignant Pleural Mesothelioma, H2 2012 9
Products under Development for Malignant Pleural Mesothelioma – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 26
Assessment by Combination Products, H2 2012 27
Assessment by Route of Administration, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Molecule Type, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 31

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos